Home
Novelion Therapeutics Inc.

Novelion Therapeutics Inc. Market Share Analysis for February 2026

the investor relations website contains information about novelion therapeutics's business for stockholders, potential investors, and financial analysts.

Health > Biotechnology and Pharmaceuticals

Domainnovelion.com

Year Founded1981

Employees201 - 500

Annual Revenue$100M - $200M

Novelion Therapeutics Inc.

Novelion Therapeutics Inc. (including company regionals)

novelion.com

See more website traffic and engagement information

Novelion Therapeutics Inc. Revenue up to February 2026 is 100M - 200M

revenue generated by Novelion Therapeutics Inc. top domains

Novelion Therapeutics Inc. top domains revenue over 3 years

Revenue for Novelion Therapeutics Inc. top domains

novelion.com100M - 200M

See more with Sales Intelligence

Total visits to Novelion Therapeutics Inc.'s top domains

Understand Novelion Therapeutics Inc. market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Novelion Therapeutics Inc.'s top domains

Analyze Novelion Therapeutics Inc. engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Novelion Therapeutics Inc.'s top domains

See how Novelion Therapeutics Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Novelion Therapeutics Inc. top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Novelion Therapeutics Inc.

These are the website technologies, by industry, used by Novelion Therapeutics Inc. top domains

Content Management System (3)

Drupal

Advertising (2)

Google Adsense

Conversion & Analytics (2)

Google Analytics

Payment & Currencies (2)

Euro

More Technologies

8

See all

News & Signals from Novelion Therapeutics Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsNovelion Therapeutics Inc. promotes Juxtapid.According to federal prosecutors, Aegerion sales employees promoted Juxtapid as a treatment for high cholesterol generally, which was not consistent with the drug's narrow, FDA-approved label for patients with a rare genetic condition called homozygous familial hypercholesterolemia.

NewsNovelion Therapeutics Inc. hires Price as executive vice president and chief financial officer.Before joining Akcea, Mr. Price served as executive vice president and CFO and was elected to the company's board of directors of Novelion Therapeutics.

NewsAmryt Pharma plc acquired Novelion Therapeutics Inc. for $60M on Jan 1st '19.It's a period in which Amryt completed the acquisition of Aegerion Pharmaceuticals Inc and saw the firm go from a single-product, Europe-focused business to an operation with infrastructure around the world and two orphan treatments.